AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Radiopharm has announced the appointment of Dr Sherin Al-Safad as Vice President Medical and Corporate Affairs.
- She held leadership roles at multinational biotechnology and pharmaceutical companies.
- RAD shares gained over 4.5% in the morning hours.
Australian radiopharmaceutical products developer Radiopharm Theranostics Limited (ASX: RAD) has appointed Dr Sherin Al-Safad as Vice President Medical and Corporate Affairs, effective 24 July 2023. Dr Al-Safadi carries extensive experience in the pharmaceuticals and biotechnology space.
Dr Al-Safadi has a doctorate degree in neurobiology from Concordia University. She is a MSc in Pharmacology from McGill University and an MBA from the John Molson School of Business in Entrepreneurship & Management.
Rich industry experience
The most recent role of Dr Al-Safadi was Vice-President – Medical Affairs at POINT Biopharma, where she assembled and led a medical affairs division. At POINT, she led the strategic planning for Phase III support and launch preparation of radiopharmaceuticals. She also offered leadership and strategic input for business development and licencing opportunities.
Currently, she is serving at Foundation Amal (Canada-USA) as co-founder and president and managing an executive leadership team (12 directors and members). She has overseen the firm’s successful 2021 cross-border expansion into the United States and led the development of branding and communication strategy.
Previously, she was Director of Global Medical Affairs Oncology at Bayer. During her time there, she led franchise-specific strategic guidance and Key Performance indicators for Med affairs teams launch excellence. It incorporated the transition to hybrid digital engagement.
RAD shares traded at AU$0.110 on 24 July 2023.